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or expertise, overlap with disease in other ter‑
ritories or organs, which thus all naturally be‑
come areas of common medical concern and, if 
indicated, intervention. Cardiac and vascular 
surgeons, interventional neurologists, radiolo‑
gists, angiologists, and cardiologists all address 
similar pathologies while taking care of these 
patients with a multilevel disease.3
In the current issue of Kardiologia Polska (Kar-
diol Pol), Vlajinac et al4 report on the incidence 
of multisite atherosclerosis in 1045 consecutive 
patients referred for evaluation of carotid ste‑
nosis or peripheral arterial disease. Building on 
the epidemiology noted in the inaugural report 
by Aronow and Ahn5 quarter of a century ago 
and then followed by larger ‑scale registries such 
as the Reduction of Atherothrombosis for Con‑
tinued Health (REACH), the data reported by Vl‑
ajinac et al4 clearly demonstrate that the risk pro‑
file of patients with PVD is significantly worse 
than in those with single ‑territory atheroscle‑
rotic involvement, thus calling for an earlier 
and more thorough workup of the PVD cohort. 
As angiographic evaluation and clinical treat‑
ment of atherosclerotic disease evolve,6 contem‑
porary investigations such as that by Vlajinac et 
al4 are critically needed to monitor and under‑
stand new developments in order to adequate‑
ly address novel challenges.2
The heart is central to PVD not simply be‑
cause of its anatomic location. Today, patients 
effectively treated for peripheral arterial dis‑
ease or cerebrovascular disease can successful‑
ly avoid limb amputation or carotid stenosis‑
‑related stroke only to experience premature 
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Despite extensive research and ongoing orga‑
nizational efforts, cardiovascular disease re‑
mains—and will remain for at least the next 25 
years—the leading cause of death, including pre‑
mature death.1,2 Cardiovascular disease also re‑
mains the leading cause of disability, with isch‑
emic stroke being the primary cause.2 The soci‑
etal cost of cardiovascular disease is substantial‑
ly higher than that of cancer, and is predicted 
to increase even further.2 There is no doubt that 
novel therapies are needed to address the grow‑
ing cardio‑vascular disease burden,1 but equally 
pressing is the conduction of well ‑designed reg‑
istries that would enable understanding the rea‑
sons for suboptimal implementation of many 
existing therapies.2 Today, the knowledge gen‑
erated from all ‑comer registries and studies is 
fundamental. 
A significant part of the growing problem with 
cardiovascular disease lies in the increase in 
multisite atherosclerotic involvement, known 
as polyvascular atherosclerotic disease (PVD). 
In patients with PVD, the risk of death due to 
cardiac events is doubled compared with those 
with “isolated” coronary artery disease (CAD).3 
These days, in PVD patients, regional lesions 
that previously garnered attention because of 
the individual physician’s special field of interest 
Correspondence to: 
Piotr Musiałek, MD, DPhil, 
FESC, Deptartment of 
Cardiac and Vascular Diseases, 
Institute of Cardiology, 
Jagiellonian University Medical 
College, John Paul II Hospital, 
ul. Prądnicka 80, 31-202 
Kraków, Poland, phone: 
+48 12 614 22 87, email: 
pmusialek@szpitaljp2.krakow.pl
Received: October 17, 2019.
Accepted: October 18, 2019.
Published online: 
October 24, 2019.
Kardiol Pol. 2019; 77 (10): 899-901
doi:10.33963/KP.15034
Copyright by the Author(s), 2019
E D I T O R I A L
The cardio‑vascular future of panvascular 
medicine: the basics
Piotr Musiałek1, Lance Montauk2, Antoine Saugnet3, Antonio Micari4, L. Nelson Hopkins5
1 Department of Cardiac and Vascular Diseases, Institute of Cardiology, Jagiellonian University Medical College, John Paul II Hospital, Kraków, Poland
2 Medical Center Emergency Services, University of California San Francisco, San Francisco, California, United States
3 Cardiologie Générale et Interventionnelle, Clinique Pasteur, Toulouse, France
4 Clinical Institute Humanitas Gavazzeni, Bergamo, Italy
5  Departments of Neurosurgery and Radiology, School of Medicine and Biomedical Sciences, University at Buffalo, State University 
of New York, Jacobs Institute, Gates Vascular Institute Kaleida Health, Buffalo, New York, United States
KARDIOLOGIA POLSKA 2019; 77 (10)900
foramen ovale closure, left atrial appendage 
occlusion, or neuro ‑protected carotid artery 
stenting); 2) the “no ‑delay” mindset of inter‑
ventional cardiologists that they developed 
with primary angioplasty in acute MI, and their 
true 24 / 7 / 365 operating hours schedule; and 
3) the “en route to the brain” skills and exper‑
tise of those particular interventional cardiol‑
ogists who already perform, with low compli‑
cation rates, complex neuroprotected cephal‑
ic artery interventions. Although MT is essen‑
tially similar to coronary thrombus aspiration 
in acute MI, it needs to be fully understood 
and appreciated that the brain is not the heart, 
the cerebral arteries are not epicardial, and AIS 
is not an acute MI.11,14,16 While those interven‑
tional cardiologists (along physicians of oth‑
er vascular specialties such as vascular sur‑
gery and interventional angiology) with a high 
level of neuroprotected carotid artery stent‑
ing skills still require additional training to 
perform AIS ‑MT,12,15 the MT training of inter‑
ventional cardiologists skilled in coronary ar‑
tery manual thrombus aspiration and in neuro‑
protected carotid artery stenting takes approx‑
imately 3 months, whereas it takes around 3 to 
4 years of instruction and experience to fully 
train someone with no endovascular skills to 
become a neurointerventionalist (providing 
the person turns out capable of acquiring such 
skills). Cardiac cathlab‑based MT ‑capable cen‑
ters working under the guidance of current in‑
ternational AIS guidelines (cf, thrombectomy‑
‑capable centers in parallel to comprehensive 
stroke centers17); have AIS ‑MT results similar 
to the “classic” neurointerventional centers.18,19 
Unfortunately, even if cardiologists are proper‑
ly trained and are part of an already established 
collaboration program with a local stroke unit, 
they often face political obstructions and ter‑
ritorial turf issues from other specialties, in‑
cluding interventional radiology, neurosurgery, 
and neurology.14 The latter is especially incon‑
gruous given most neurologists are noninter‑
ventionalists, have no desire to become such, 
and their prime concern should be the fate of 
the stroke patients who come to their attention 
in acute clinical setting.14,16
In conclusion, the heart is central to pan‑
vascular medicine not only anatomically but 
also logistically, and, of course, prognosti‑
cally.7, 8,11 Cardiology provides a range of es‑
tablished processes from prevention and uti‑
lizing evidence ‑based and patient ‑centered 
pharmacotherapy to the expertise and infra‑
structure to perform elective and emergent 
skilled endovascular interventions. Cardiolo‑
gists, along other endovascular intervention‑
alists, intervene caudally from the heart to‑
wards the kidneys, centrifugally to the low‑
er and upper extremities, and cephallical‑
ly to the brain. One high ‑level professional 
death from CAD.7,8 Optimal cardiac care, includ‑
ing coronary revascularization, may reduce CAD 
death in patients with cerebrovascular / periph‑
eral arterial disease,7 calling for greater involve‑
ment of general and interventional cardiology in 
managing patients with PVD. Such involvement 
appears particularly relevant as many patients 
with cerebrovascular / peripheral arterial disease 
do not exhibit CAD symptoms due to their re‑
duced mobility and a high prevalence of diabe‑
tes.7-9 Because of this, in many cardiology cen‑
ters, diagnostic workup of CAD (and, if indicat‑
ed, coronary revascularization) in patients with 
PVD is already routinely performed.8,9
Easily ‑applicable, nontroublesome CAD risk 
screening methods may exist for centers where 
cerebrovascular or peripheral arterial disease 
interventions are performed by noncardiolo‑
gists. According to a recent report, in patients 
subjected to endovascular interventions for crit‑
ical limb ischemia performed by an angiologist, 
a clinically silent periprocedural troponin rise 
was independently associated with an approxi‑
mate 2‑ to 3‑fold increase in 1‑year mortality.10 
This calls for routine peri ‑intervention troponin 
monitoring to trigger swift referrals for CAD 
evaluation and management, potentially reduc‑
ing the CAD death risk.7
The leading vascular medicine topic of today 
is acute ischemic stroke (AIS). AIS is not a dis‑
ease of neurons per se, but rather a vascular dis‑
ease of the brain, just as critical limb ischemia 
is a vascular disease of the limb, and renal in‑
sufficiency stemming from renal artery steno‑
sis is a vascular disease of the kidney. Manual 
thrombectomy (MT), the endovascular remov‑
al of the clot blocking the major cerebral artery 
in AIS, is, in patients who qualify, a highly effec‑
tive treatment (number needed to treat <3) that 
reduces (and may totally prevent) stroke ‑related 
disability and suffering.11 Time to intervention is 
a key factor determining success in AIS (to an ex‑
tent far greater than in the acute myocardial in‑
farction [MI]), and one of the worst things that 
can be done to a patient with AIS is interhospi‑
tal transportation, particularly if MT facilities 
already exist in the hospital where the patient 
originally presents.11 Today, lack of personnel to 
deliver MT is the primary reason for limited MT 
availability in European countries with subopti‑
mal AIS management, including Poland,12 a coun‑
try that once internationally championed acute 
MI revascularization networks and developed 
treatment paradigms.
Cardiology is naturally positioned for AIS 
management to fill the embarrassing gap be‑
tween MT needs and current delivery12,13 for 
a number of reasons14 -16 including: 1) the role 
of cardiology in primary and secondary AIS 
prevention (such as pharmacologic and inter‑
ventional management of atrial fibrillation to 
note arrhythmic substrate ablations, patent 
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organization that consequently implements 
multispecialty inclusive policies and devel‑
ops integrated guidelines that involve vascu‑
lar surgeons, angiologists, stroke physicians, 
diabetologists, and others is the European So‑
ciety of Cardiology. This is an attitude increas‑
ingly adopted by others such as the American 
Heart Association / American Stroke Associa‑
tion. In a growing number of vascular centers, 
cardiology effectively brings together differ‑
ent specialties at the bedside and in the op‑
erating room.15 Also, there are some very im‑
portant initiatives of cardiology physicians 
such as the FRIENDS (Finalised Research in 
Endovascular Strategies) initiative that up‑
lifts the every ‑day multispecialty collabora‑
tion at the level of an individual patient care 
to the level of clinical studies that generate 
new panvascular knowledge to guide patient 
management.3
The shortage of interventionalists capable of 
rapidly treating patients with stroke constitutes 
a critical bottleneck contributing to a severe public 
health problem.13,14 This and other barriers in our 
healthcare systems, including the (sadly) human‑
‑generated ones (note some continued attempts 
to decide who “can” and who “cannot” or who 
“should” and who “should not” perform a partic‑
ular type of endovascular intervention)14-16 pro‑
duce, in case of AIS, ever more severely disabled 
patients. Interventional cardiologists, and espe‑
cially those already skilled in accessing and treat‑
ing supra ‑aortic anatomy, are currently—accord‑
ing to patient ‑centered neuroradiology key opin‑
ion leaders—best ‑positioned tactically and stra‑
tegically to achieve rapid intervention for AIS 
nationwide.14,16 Hampering their involvement is 
a detriment to individual and public health.
Creation of multispecialty stroke referral and 
management networks including (consistent 
with international guidelines such as the Amer‑
ican Stroke Association guidelines17) establish‑
ment of interventional cardiology cathlab ‑based 
MT ‑capable centers working in a close collabo‑
ration with local stroke units, remains an un‑
finished job.14,16 This unfinished work, in many 
countries (including Poland),12 translates into 
a continued and systematic production of pre‑
ventable invalids in place of people enjoying 
normal (or nearly ‑normal) lives after a timely 
and effective MT.
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